{
  "docId": "019de071-675b-766f-be4a-046f8bf2051e",
  "docSlug": "b31f49935b4e527920acfe5c29480f2e",
  "documentTitle": "Genetron | Results Presentation Deck | 23 slides",
  "authorId": "genetron",
  "authorName": "Genetron",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 23,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The chart illustrates the superior sensitivity of NGS (red line) compared to MFC and PCR in detecting malignant cells over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-675b-766f-be4a-046f8bf2051e/8",
  "deckHref": "/decks/019de071-675b-766f-be4a-046f8bf2051e",
  "deckJsonHref": "/decks/019de071-675b-766f-be4a-046f8bf2051e.json",
  "deckAnchorHref": "/decks/019de071-675b-766f-be4a-046f8bf2051e#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.53,
        "y": 0.0045
      },
      "kind": "chart",
      "text": "Proportion of Malignant Cells vs Time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af6f0198-aac1-4556-80c9-77a039341867",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.48,
        "x": 0.02,
        "y": 0.0015
      },
      "kind": "diagram",
      "text": "Seq-MRD Workflow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28b1aa9a-371a-4a08-ac9a-12e5ccd442dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.53,
        "y": 0.0017
      },
      "kind": "list",
      "text": "Leveraging our One-Step Seq technology, Seq-MRD can be used to detect and monitor MRD in patients with hematological tumor. Seq-MRD provides more accurate evidence for early treatment response and recurrence prediction. Inked a partnership with a leading MNC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bac410d-096c-4b1c-8eb7-c83e8b9b638b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.0063
      },
      "kind": "list",
      "text": "High sensitivity and stability; Simple operation, low risk of contamination; Wide clonotype coverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a69a3af1-816c-4a5e-a7a2-34ffb3ca6486",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.13,
        "x": 0.86,
        "y": 0.008199999999999999
      },
      "kind": "source-note",
      "text": "Source: Short, NJ, Jabbour, E, Albitar, M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "681a9812-27c1-412a-a325-8c4339ef23f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Multi Advantages in Seq-MRD® with \"One-Step Seq\" Method",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc5ccb8c-2076-451c-8abd-0589014e0acb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 6,
      "beatId": "2ac6fe70-2992-4519-b150-e5025d849888",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The discussion of HCCscreen and Seq-MRD highlights the need for innovative solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b12199cf-4b96-4c2d-a175-f0182ab54bd2",
      "evidence": "The discussion of HCCscreen and Seq-MRD implies the risks of not adopting these solutions",
      "position": 0,
      "objective": "What are the consequences of not adopting innovative solutions?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}